Iovance Biotherapeutics (IOVA) Stock Forecast, Price & News

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IOVA shares.
View IOVA analyst ratings or view top-rated stocks.

11 analysts have issued 12 month price targets for Iovance Biotherapeutics' stock. Their IOVA share price forecasts range from $6.00 to $38.00. On average, they predict the company's stock price to reach $19.09 in the next year. This suggests a possible upside of 116.9% from the stock's current price.
View analysts price targets for IOVA or view top-rated stocks among Wall Street analysts.

Iovance Biotherapeutics' stock was trading at $6.39 at the start of the year. Since then, IOVA shares have increased by 37.7% and is now trading at $8.80.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our IOVA earnings forecast.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) issued its quarterly earnings data on Tuesday, May, 9th. The biotechnology company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.84) by $0.34. During the same quarter last year, the business posted ($0.58) EPS.

ETFs with the largest weight of Iovance Biotherapeutics (NASDAQ:IOVA) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), iShares Genomics Immunology and Healthcare ETF (IDNA), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Harbor Disruptive Innovation ETF (INNO), Principal Healthcare Innovators ETF (BTEC) and ARK Genomic Revolution ETF (ARKG).

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Iovance Biotherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (6.83%), State Street Corp (6.12%), BlackRock Inc. (5.55%), Price T Rowe Associates Inc. MD (1.67%), Boxer Capital LLC (1.65%) and Artisan Partners Limited Partnership (1.59%). Insiders that own company stock include Frederick G Vogt, Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum.
View institutional ownership trends.

Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IOVA stock can currently be purchased for approximately $8.80.

Iovance Biotherapeutics (NASDAQ:IOVA) has a market capitalization of $1.98 billion. The biotechnology company earns $-395,890,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis.

The company employs 319 workers across the globe.

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The official website for the company is www.iovance.com. The biotechnology company can be reached via phone at (650) 260-7120 or via email at achang@troutgroup.com.